Title :

National diagnostic and care protocols (NDCP) for hematopoietic stem cell transplantation in autoimmune diseases.

Author(s) :

Farge, D. [Auteur]
Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH) [IRSL]
McGill University = Université McGill [Montréal, Canada]
Pugnet, G. [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Allez, M. [Auteur]
Hôpital Saint-Louis
Castilla-Llorente, C. [Auteur]
Département d'hématologie [Gustave Roussy]
Chatelus, E. [Auteur]
Service de rhumatologie [Strasbourg]
Cintas, P. [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Faucher-Barbey, C. [Auteur]
Agence de la biomédecine [Saint-Denis la Plaine]
Labauge, P. [Auteur]
Université de Montpellier [UM]
Labeyrie, C. [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Lioure, B. [Auteur]
Département d'Oncologie et Hématologie [Strasbourg]
Maria, A. [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Michonneau, D. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Puyade, M. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Talouarn, M. [Auteur]
Immunochimie des Régulations Cellulaires et des Interactions Virales [Inserm U354/Hôpital Saint-Antoine-APHP]
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Treton, X. [Auteur]
Hôpital Beaujon [AP-HP]
Wojtasik, G. [Auteur]
Hôpital Claude Huriez [Lille]
Zephir, Helene [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Marjanovic, Z. [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Rev Med Interne

Abbreviated title :

Rev Med Interne

Publication date :

2024-01-16

ISSN :

1768-3122

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and ...
Show more >Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease. The aim of this document was to provide guidelines for the current indications, procedures and follow-up of HSCT in ADs. Patient safety considerations are central to guidance on patient selection and conditioning, always validated at the national MATHEC multidisciplinary team meeting (MDTM) based on recent (less than 3months) thorough patient evaluation. HSCT procedural aspects and follow-up are then carried out within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and SFGM-TC accredited centres in close collaboration with the ADs specialist. These French recommendations were performed according to HAS/FAI2R standard operating procedures and coordinated by the Île-de-France MATHEC Reference Centre for Rare Systemic Autoimmune Diseases (CRMR MATHEC) within the Filière FAI2R and in association with the Filière MaRIH. The task force consisted of 3 patients and 64 clinical experts from various specialties and French centres. These data-derived and consensus-derived recommendations will help clinicians to propose HSCT for their severe ADs patients in an evidence-based way. These recommendations also give directions for future clinical research in this area. These recommendations will be updated according to newly emerging data. Of note, other cell therapies that have not yet been approved for clinical practice or are the subject of ongoing clinical research will not be addressed in this document.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Neuroinflammation & Multiple Sclerosis (NEMESIS)

Submission date :

2024-02-09T22:15:16Z
2024-09-04T08:09:54Z